Cardiovascular: Strategic Biosimulation Services

Certara has performed over 80 projects in modeling and simulation to support cardiovascular drug development across all phases of clinical development. Our consultants have addressed key issues in trial design, dose selection, and development strategy for a broad range of cardiovascular diseases and conditions, including pulmonary arterial hypertension (PAH), congestive heart failure (CHF), hypertension, deep vein thrombosis (DVT), and hyperlipidemia. Our compilations of public data from the clinical and scientific literature in several cardiovascular indications provide a ready context for model-based meta-analysis to assess your compound's performance against competing therapies.

Number and types of projects

  • 81 projects
  • Type - small molecules and biologics
  • Mechanism of Action - Factor Xa inhibitors, angiotension II receptor antagonist, β1-selective β Blocker, ROMK inhibitor, nitric oxide donor, calcium channel blocker, PDE5 inhibitor, competitive PAR-1 antagonist, ACE inhibitor, vasodilator, thromboxane A2 receptor antagonist, PPAR ligands, erythropoietin stimulating agents
  • Disease areas
    • Acute cardiac failure
    • Acute coronary syndrome (ACS), coronary artery disease
    • Angina, stable angina pectoris
    • Cardiac arrhythmias
    • Blood loss during cardiopulmonary surgery
    • Congestive heart failure (CHF)
    • Deep vein thrombosis (DVT)
    • Dyslipidemia, hyperlipidemia, hypertriglyceridemia
    • Hypertension, isolated systolic hypertension (ISH)
    • Non-valvular atrial fibrillation (NVAF)
    • Pulmonary arterial hypertension (PAH)
    • Stroke
    • Thrombosis

Advances in biosimulation technology are ushering in a new era for cardiovascular drug development. Certara Consulting Services can leverage this approach to help you make data-driven decisions at all stages of your drug's development.